TY - JOUR
T1 - Kidney cancer
T2 - Toxicity management, symptom control, and palliative care
AU - Sinibaldi, Victoria J.
AU - Pratz, Caroline F.
AU - Yankulina, Olga
N1 - Publisher Copyright:
© 2018 by American Society of Clinical Oncology
PY - 2018/12/20
Y1 - 2018/12/20
N2 - The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.
AB - The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.
UR - http://www.scopus.com/inward/record.url?scp=85058560588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058560588&partnerID=8YFLogxK
U2 - 10.1200/JCO.2018.79.0188
DO - 10.1200/JCO.2018.79.0188
M3 - Review article
C2 - 30372391
AN - SCOPUS:85058560588
SN - 0732-183X
VL - 36
SP - 3632
EP - 3638
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 36
ER -